HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

NeurologyLive Friday 5 — January 8, 2021

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 8, 2021.

Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: How Pharmaceutical Innovation Is Saving the World

Mike Hennessy Sr, Founder and Chairman, MJH Life Sciences, penned an op-ed praising the efforts of the medical and pharmaceutical communities for their swift action in developing vaccines in record time for COVID-19.

2: Michael Okun, MD: Importance of Disease-Based Registries

The executive director of the Norman Fixel Institute for Neurological Diseases explained how disease-based registries play a crucial part in changing the approval system for neurologic devices in rare diseases.

3: The Significance of 5-HT1F Agonist Approval

A discussion with Amaal Starling, MD, on the significance of the approval of a 5-HT1F agonist, with special consideration of the safety and efficacy from the respective clinical trial.

4: Out-of-Pocket Costs Steadily Increasing for Neurologic Care

A recent analysis of UnitedHealthcare insurance claims revealed increases of almost 200% for some services between 2001 and 2016.

5: Choosing Cannabidiol or Fenfluramine for Dravet

M. Scott Perry, MD, reviews how cannabidiol and fenfluramine are chosen for patients with Dravet syndrome based on concomitant medications and associated adverse events.